Company Profile - Sosei Heptares

Introduction

Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. Its medical products include Ultibro, Seebri, Enerzair, Breezhaler, and Oravi. The company's in-house pipeline programs include H4 antagonist, EP4 antagonist, SARS-CoV-2 MPro, GPR52 agonist and PAR2 mAb. Sosei partnered pipeline program comprises Adenosine A2a antagonist, GLP-1 agonist, CCR6 antagonist, MC4 antagonist, CGRP antagonist, GPR35 agonist, CXCR4 mAb, PAR2 Peptide, targeted GPCR degradation, AI-augmented drug discovery, Ion Channels, mGlu5 NAM and OX2 agonists. It develops medicines in the therapeutic areas of gastroenterology, neurology, immunology and inflammatory diseases. The company operates in Japan, Ireland and the UK. Sosei is headquartered in Chiyoda-ku, Tokyo, Japan.